Percheron Therapeutics Limited has released a press release.
Quarterly Update and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Annual General Meeting Chairmans Address
- EC grants Orphan Drug Designation for ATL1102 in DMD
- Receipt of R&D Tax Incentive payment
- ANP raises A$7.3 million from Oversubscribed Placement
- ANP to apply for dual listing on Frankfurt Stock Exchange
Later from Percheron Therapeutics
- ANP meeting with US FDA granted for ATL1102 in DMD
- Half Yearly Report and Half Year Accounts
- ATL1102 DMD Paediatric Investigation Plan submitted to EMA
- US FDA Type C Meeting for ATL1102 in DMD
- Manufacture of ATL1102 clinical supplies for Phase IIb trial
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics